Biotech2 months ago
Baxter Sells its Renal Care Subsidiary to Carlyle for $3.8 Billion
Baxter plans to sell its renal business by early 2025 to reduce debt, continuing its strategy of divesting subsidiaries, including a $3.857 billion sale of Biopharma...